{
  "ticker": "CYP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976846",
  "id": "02976846",
  "pages": 15,
  "price_sensitive": false,
  "date": "20250805",
  "time": "0832",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250805/pdf/06mjph6w2my9vh.pdf",
  "summary": "### Summary of ASX Announcement:  \n**Investor Webinar Announcement**  \n- No material trading or capital markets information disclosed.  \n\n**Presentation Highlights (Appendix 4C Equivalent):**  \n- **Cash Runway**: Secure funding until mid-2026.  \n- **Clinical Milestones**:  \n  - **CYP-001 (aGvHD)**: Phase 2 enrolment >75% complete; primary results expected 1H 2026.  \n  - **CYP-004 (Osteoarthritis)**: Phase 3 enrolment complete; final results expected Feb\u2013Apr 2026; potential TGA approval pathway indicated.  \n  - **CYP-001 (Kidney Transplantation)**: Cohort 1 data review by Q4 2025.  \n- **Preclinical Data**: Positive results for heart disease treatment using MSC-derived factors.  \n\n**Capital Structure**:  \n- **Market Cap**: ~A$38m (225m shares @ A$0.17).  \n- **Top Holders**: Top 20 shareholders own ~47% (Fidelity, BioScience Managers, Fujifilm).  \n\n**Catalysts**:  \n- Three clinical trial readouts expected within FY2026 (aGvHD, osteoarthritis, kidney transplantation).  \n\n**No material capital-raising, trading halt, or significant liquidity/capital structure updates identified.**",
  "usage": {
    "prompt_tokens": 3284,
    "completion_tokens": 279,
    "total_tokens": 3563,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-04T22:56:27.592731"
}